Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
In the event you’ve just lately obtained a wage bump, congratulations! An rising wage is likely one of the keys...
Bangladesh started the primary trial on Sunday at a particular courtroom prosecuting former senior figures linked to the ousted authorities...
© 2025 Fortune Media IP Restricted. All Rights Reserved. Use of this web site constitutes acceptance of our Phrases of...
After the detection of COVID-19 instances in few southern and western states, the Union Well being Secretary was realized to...
Might 24, 2025 1:45 PM ETCOST, TGT, XLP, HD, HPQ, NVDA, CRM, AZO, LOW, MDT, ULTA, XLRE, DELL, XLCBy: Deepa...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
